Moleculin Reports Full Year 2023 Financial Results menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
HOUSTON - Moleculin Biotech, Inc., , a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced the.
100% overall response rate and 70% complete response rate observed in standard of care relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy in updated Phase.
Moleculin Biotech (MBRX) Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The European Commission has granted a label expansion of the combination treatment KAFTRIO® with ivacaftor, for children aged two to five years old with cystic fibrosis. The treatment from .